In a pregnant woman with non‑transfusion‑dependent thalassemia, at what hemoglobin level should red blood cell transfusion be initiated and what target hemoglobin should be maintained throughout pregnancy?

Hemoglobin Threshold for Transfusion in Pregnant Women with Non-Transfusion-Dependent Thalassemia

In pregnant women with non-transfusion-dependent thalassemia, maintain hemoglobin ≥10 g/dL throughout pregnancy with red blood cell transfusions to ensure optimal fetal growth and prevent maternal complications 1.

Transfusion Strategy

The American Heart Association consensus statement on β-thalassemia major explicitly recommends maintaining hemoglobin at approximately 10 g/dL during pregnancy 1. This target applies directly to pregnant women with thalassemia, as blood consumption increases during pregnancy to support fetal growth, and the interruption of chelation therapy (due to teratogenic concerns) can worsen iron overload.

Key Hemoglobin Targets:

• Initiate transfusion when: Hemoglobin falls below 10 g/dL
• Maintain throughout pregnancy: Hemoglobin ≥10 g/dL
• Transfusion frequency: Typically requires increased frequency compared to pre-pregnancy state

Supporting Evidence and Clinical Context

Research data from real-world practice demonstrates that:

• In one study of 36 pregnancies with NTDT, the lowest mean hemoglobin without transfusion was 8.21 g/dL, though 41.6% of pregnancies still required no transfusion 2
• However, maintaining hemoglobin ≥10 g/dL has been shown to minimize complications for both mother and baby 3
• The mean number of transfusions during pregnancy ranges from 6.95 to 8.0 units per pregnancy 2, 4

The 10 g/dL threshold is critical because:

• Prevents intrauterine growth restriction (IUGR), which complicates 47.6-57.1% of pregnancies when hemoglobin is inadequately maintained 4, 5
• Reduces risk of preterm delivery (38.1% in undertreated cases) 5
• Minimizes maternal cardiac complications (1.1-15.6% incidence) 1
• Prevents severe anemia-related complications requiring ICU admission 5

Important Clinical Pitfalls

Transfusion Complications to Monitor:

1. Alloimmunization risk: Patients may develop antibodies during pregnancy, even if previously non-transfused, contributing to worsening anemia and increased transfusion requirements 4

2. Iron overload: Despite interrupting chelation, monitor cardiac function carefully. Consider restarting deferoxamine toward the end of the second trimester in patients with severe cardiac or hepatic iron overload 1

3. Thromboembolism prophylaxis: Mandatory heparin or low-molecular-weight heparin, particularly in splenectomized patients 1

Pre-Pregnancy Assessment Required:

Before conception, assess cardiac T2* and cardiac function, as iron overload-related cardiac complications pose significant maternal risk 1. The increased blood volume and hemodynamic changes of pregnancy can compromise cardiac function in iron-overloaded patients.

Neonatal Outcomes with Adequate Transfusion

When hemoglobin is maintained ≥10 g/dL with appropriate multidisciplinary care:

• Mean gestational age: 38.6 weeks 2
• Mean birth weight: 2729 grams 2
• Successful delivery of live-born neonates in properly managed cases 2

Conversely, inadequate hemoglobin maintenance results in:

• Low birth weight (61.9% vs 4.8% in controls) 5
• NICU admission (89.4% vs 15.8% in controls) 5
• IUGR (47.6% vs 4.1% in controls) 5

The evidence strongly supports aggressive transfusion management to maintain hemoglobin ≥10 g/dL throughout pregnancy, even in patients who were previously non-transfusion-dependent, as pregnancy fundamentally changes the risk-benefit calculation 1, 3, 4.